

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 March 2003 (06.03.2003)

PCT

(10) International Publication Number
WO 2003/019144 A3

(51) International Patent Classification:

A61K 31/4 (2006.01) G01N 33/574 (2006.01)
C12Q 1/00 (2006.01)

(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., One Financial Center, Boston,
MA 02111 (US).

(21) International Application Number:

PCT/US2002/027208

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 27 August 2002 (27.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/315,198 27 August 2001 (27.08.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European patent (AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:

US 60/315,198 (CIP)
Filed on 27 August 2001 (27.08.2001)

Published:


— with international search report

(71) Applicants and

(72) Inventors: BISWAS, Debajit, K. [US/US]; 100 Prospect
Street, Newton, MA 02465 (US). PARDEE, Arthur, B.
[US/US]; 30 Codman Road, Brookline, MA 02445 (US).

(88) Date of publication of the international search report:
18 June 2009

(54) Title: METHODS AND COMPOSITIONS FOR SCREENING, DIAGNOSING, OR TREATING NF- κ B RELATED DISEASE



(57) Abstract: A method of screening, diagnosing, or treating an NF- κ B induced pathology through the use of NF- κ B modulating agents. These cells isolated from pathological regions of a subject can be cultured in the presence or absence of a modulating agent to detect a change in proliferation of the cells, wherein a change in proliferation in modulator treated cells compared to control cells shows that the cells are derived from an NF- κ B induced pathology. A subject that contains cells derived from an NF- κ B induced pathology can be diagnosed with this pathology. NF- κ B modulators can then be used to treat the NF- κ B induced pathology.

WO 2003/019144 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/27208

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/4; C12Q 1/00, 3/00; G01N 33/574

US CL : 514/410, 435/375, 7.23, 4

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/410, 435/375, 7.23, 4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BISWAS et al. Epidermal growth factor-induced nuclear factor kappaB activation: A - major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA, 18 July 2000, Vol. 97, No. 15, pages 8542-7, especially abstract, Fig. 6, page 8543 left column. line 11.	1-6, 8, 27
X --- A	BISWAS et al. The nuclear factor kappa B (NF-kappaB): Apoptical therapeutic target forestrogen receptor negative breast cancers, Proc. Natl. Acad. Sci. USA, 28 August 2001, Vol. 98, No. 18, pages 10386-10391.	1-23, 25 ----- 24, 26, 28-43, 35-37
X	US 5,489,608 A (KLEINSCHROTH et al) 6 February 1996 (06.02.1996), abstract, columns 3-8.	1-6

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

06 March 2003 (06.03.2003)

Date of mailing of the international search report

26 MAR 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

MISOOK YU, Ph.D.

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/27208

Continuation of B. FIELDS SEARCHED Item 3:

Dialog (5, 155, 159) and West (US Pat)

Search terms: estrogen receptor negative cancer, nuclear factor kappa B, kinase inhibitor, go6976, breast cancer.